Nottingham University’s ocular wound spinout NuVision has raised £379,000 ($590,000) in a seed round backed by Mercia Fund Management, a serial investor in UK spinouts.
The spinout is the result of 13 years of research at Nottingham which has culminated in Omnigen, a membrane-derived biological bandage that can applied to ocular wounds such as scratches and burns as soon as they occur.
With the ability to be applied in emergency wounds, Omnigen can be used to quickly relieve pain and stabilise an injury, and be used in both medical and veterinary settings.
Peter Dines, head of life sciences at Mercia Fund Management, said: “NuVision is the perfect example of the potential that university spinouts have in the UK – a great team, innovating research and a product set to revolutionise ophthalmic care worldwide are just a few of the reasons why we chose to back NuVision with seed funding. We look forward to supporting them as they begin to commercialise Omnigen and the Tereo process.”
